In a significant breakthrough for oncology and molecular biology, a multidisciplinary team of investigators at the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins Bloomberg School of Public Health has identified the specific mechanism by which certain gene rearrangements drive the progression of a rare and aggressive form of kidney cancer. The study, published on April 22 in the journal Cell Reports, reveals that proteins produced by these "fusion genes" aggregate into microscopic liquid droplets within the cell nucleus. These droplets, known as liquid condensates, act as command centers that abnormally activate genes responsible for cancer growth and metastasis. This discovery not only sheds light on the fundamental biology of translocation renal cell carcinoma (tRCC) but also points toward a novel therapeutic strategy that could potentially be applied to a variety of other fusion-driven cancers, including certain types of leukemia and Ewing sarcoma.
The Biological Mechanism: Phase Separation and Gene Regulation
The crux of the research lies in the behavior of fusion proteins within the cellular environment. In healthy cells, gene expression is a tightly regulated process where specific proteins interact with DNA to turn genes on or off at precise moments. However, in translocation renal cell carcinoma, chromosomal rearrangements occur—essentially a biological "cut and paste" error where a segment of one chromosome is swapped with another. This results in the fusion of the TFE3 gene with one of several partner genes, such as NONO or SFPQ.
The researchers, led by senior author Danfeng "Dani" Cai, Ph.D., an assistant professor of biochemistry and molecular biology at the Johns Hopkins Bloomberg School of Public Health, discovered that these chimeric TFE3 fusion proteins possess unique physical properties. They found that these proteins undergo a process called liquid-liquid phase separation. Similar to how oil droplets form in water, these fusion proteins cluster together to form "condensates"—concentrated, membrane-less compartments that house various molecular tools required for gene activation.
Through high-resolution microscopy and fluorescent tagging, the team observed these proteins forming distinct "dots" within the cell nucleus. These dots were not merely static clusters; they were dynamic environments that recruited other essential proteins, such as markers found on active genes and transcription factors that initiate the process of protein synthesis. By concentrating these elements in a small space, the fusion proteins create a hyper-efficient "factory" for turning on genes that drive cell proliferation and migration—the hallmarks of cancer.
Understanding Translocation Renal Cell Carcinoma (tRCC)
Translocation renal cell carcinoma is a rare subtype of kidney cancer that primarily affects children and young adults, though it is increasingly being recognized in older populations. Unlike the more common clear cell renal cell carcinoma, tRCC is characterized by translocations involving the MiT family of transcription factors, most notably TFE3.
Historically, tRCC has been difficult to treat because it often presents at an advanced stage and does not respond well to the standard therapies used for other kidney cancers, such as tyrosine kinase inhibitors or certain immunotherapies. Because the disease is rare, accounting for approximately 1% to 5% of adult kidney cancer cases but up to 40% of pediatric cases, clinical trials have been limited, leaving patients with few "standard of care" options.
The Johns Hopkins study focused on the two most prevalent fusion partners of TFE3: NONO and SFPQ. Together, these two fusions account for nearly 40% of all tRCC cases. By understanding the physical structure of these specific fusion proteins, the researchers hope to bridge the gap between genetic diagnosis and effective clinical intervention.
Deciphering the Chromatin Landscape
To understand how these droplets interact with the genetic blueprint, Dr. Cai partnered with Eneda Toska, Ph.D., an assistant professor of oncology at the Johns Hopkins Kimmel Cancer Center. Their collaboration focused on the "chromatin landscape"—the way DNA is packaged inside the cell.
DNA is not a loose string; it is wrapped around proteins called histones, forming a structure known as chromatin, often described as "beads on a string." When the string is tightly wound (heterochromatin), genes are inaccessible and turned off. When it is loosely wound (euchromatin), genes are accessible and can be expressed.
Dr. Toska’s analysis revealed that TFE3 fusion proteins act as "architects" of this landscape. By creating chemical modifications on the chromatin, these proteins can force open areas of the DNA that should remain closed. Specifically, the fusion proteins bind to and redesign the chromosome landscape, interacting with target genes that promote the rapid division and movement of cells. This epigenetic remodeling ensures that the cancer cell remains in a state of constant growth and has the ability to spread to distant organs.
"We found that these fusion proteins open and close different sites on the chromatin by making chemical modifications," Toska noted. This suggests that the fusion proteins do more than just sit on the DNA; they actively rewrite the cellular instructions to favor malignancy.
The Role of the Coiled-Coil Domain
One of the most critical findings of the study involved identifying the specific part of the protein responsible for forming these liquid droplets. Using CRISPR and other gene-editing techniques, the researchers systematically removed different segments of the TFE3 fusion proteins to observe the impact on condensate formation.
They discovered that a specific structural motif—a "coiled-coil" domain (a shape where two or more alpha-helices are wrapped around each other like strands of a rope)—is the essential glue that holds the liquid droplets together. This domain is located in the segment where the TFE3 tail connects to the fusion partner (such as NONO or SFPQ).
When the researchers deleted this small coiled-coil segment, the fusion proteins lost their ability to form condensates. Without these droplets, the proteins could no longer recruit the machinery needed to activate genes. Consequently, the cancer-promoting genes remained dormant, and the cells lost their aggressive characteristics. This experiment provided definitive proof that the physical state of the protein—its ability to form a droplet—is directly linked to its oncogenic power.
Implications for Other Fusion-Driven Cancers
The findings from this study have implications that extend far beyond kidney cancer. Fusion genes are a well-known cause of several other malignancies. For example, Ewing sarcoma, a bone and soft tissue cancer that affects children, is driven by the EWS-FLI1 fusion gene. Similarly, various forms of leukemia are caused by chromosomal translocations, such as the BCR-ABL fusion in chronic myeloid leukemia.
"Other cancers, such as Ewing sarcoma and leukemia, are caused by fusion genes as well," said Dr. Cai. "It’s possible that these fusion genes form similar droplets, or condensates, that regulate genes in these cancers and could react to similar treatment strategies."
This suggests a potential "unified theory" of fusion-gene oncology. If different fusion proteins across various cancer types use the same mechanism of liquid-liquid phase separation to drive gene expression, then a drug designed to disrupt these droplets could serve as a broad-spectrum therapy for many different types of cancer.
Future Directions and Therapeutic Potential
The ultimate goal of the Johns Hopkins team is to translate these laboratory findings into a clinical treatment. Currently, there are no drugs specifically designed to disrupt liquid condensates in the nucleus of cancer cells, but this research provides the roadmap for developing them.
In future phases of the study, the team plans to identify other molecular components that reside within these TFE3 droplets. By understanding the full "inventory" of the condensate, they can begin screening for small molecules or existing drugs that might destabilize the structure. The idea is to find a "chemical wedge" that can prevent the coiled-coil domains from interacting or force the droplets to dissolve, thereby "turning off" the cancer’s engine without damaging healthy cells.
"In future work, the research team hopes to identify other components in the liquid condensates that drive the cancer, which would allow them to screen for drugs or small molecules that can disrupt these structures," the researchers stated.
Collaborative Effort and Funding
The study was a massive collaborative effort involving experts from various disciplines, including oncology, biochemistry, molecular biology, and computational genomics. Contributors included Choon Leng So, Ye Jin Lee, Wanlu Chen, and several others from the Bloomberg School of Public Health, as well as Bujamin Vokshi from the Johns Hopkins University School of Medicine and W. Marston Linehan from the National Cancer Institute.
The research was heavily supported by the National Institutes of Health (NIH), including grants from the National Institute of General Medical Sciences, the National Cancer Institute, and the National Human Genome Research Institute. Additional funding was provided by the Department of Defense Kidney Cancer Idea Development Award, the Jayne Koskinas Ted Giovanis Foundation, and the Johns Hopkins Provost Catalyst Award.
Financial disclosures noted that Dr. Toska has received grants and consulting fees from pharmaceutical companies AstraZeneca and Menarini, highlighting the interest the private sector has in these types of epigenetic and molecular discoveries.
Conclusion: A New Frontier in Oncology
The discovery that TFE3 fusion genes operate through the formation of liquid condensates marks a shift in how scientists view rare kidney cancers. It moves the focus from simply identifying a genetic mutation to understanding the physical and spatial organization of the cell’s interior. By proving that disrupting these droplets can effectively halt the activation of cancer-promoting genes, the Johns Hopkins researchers have opened a new frontier in precision medicine—one that targets the physical behavior of proteins to treat some of the most challenging diseases in oncology.
